FDA Approves Continuation of Senseonics Study on Glucose Monitoring System

Senseonics Holdings Inc., a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system—the Eversense CGM System—announced the U.S. Food and Drug Administration (FDA) approved a subgroup (with a modified chemistry to enhance longevity) of PROMISE study participants to continue for a total of 365 days to gather feasibility data on the safety and accuracy of a 365-day sensor.
 
“We are very pleased that we received a prompt approval to extend the study to gather valuable data,” said Tim Goodnow, Ph.D., president and CEO of Senseonics. “The scientific, clinical and technical data we will obtain will be critical to further extend sensor longevity. We’re very grateful to the FDA for the green light, for the tireless clinical investigators, and particularly, to the devoted study participants for giving us this opportunity.”
 
The goal of the PROMISE clinical study is to evaluate the safety and efficacy of the Eversense CGM System in people with diabetes over a 180-day period for the pre-market application submission to the FDA. One hundred and eighty-one study participants at eight sites across the United States had the Eversense CGM System inserted subcutaneously as part of the study, which completed the 180-day duration in March. Now, a sub-set of more than 35 participants who all had a sensor with the modified chemistry will be left undisturbed for 365 days with the goal of measuring accuracy and longevity over the full 365 days.
 
“Extending this study is really a critical step in developing a 365-day product. Information gathered from this cohort will allow us to characterize the improved sensor design and optimize our glucose algorithm for the extended, 365-day use period,” explained Mukul Jain, Ph.D., chief operating officer at Senseonics. “This addition is an exciting extension phase of the PROMISE study and we look forward to evaluating the first multi-clinic investigation of a one-year implantable glucose sensor.”
 
The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose and can be removed, recharged and re-attached to the skin without discarding the sensor. Eversense users now have the freedom to make treatment decisions based on their Eversense readings. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.
 
The Eversense Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a healthcare provider. The Eversense CGM System is a prescription device.